I couldn't agree more that the only deals now that have any relevance are those with up front money.
Why do you say that tene's head is in the sand? He is just reporting facts about dosage and frequency of treatment. He also just reported on what Geert said. Maybe Geert was right.
One can be optimistic and think that things will turn out well; or, one can be pessimistic about the clinical trials. tene is an optimist. You appear to be a pessimist. That does not warrant the conclusion that tene has his head in the sand.
Time will tell.
The IND for retinal scarring would bring in lots of money from licensing--or result in a buyout fairly soon. That is the hope and, I imagine, the expectation of Geert. I am optimistic that the IND will pass regulatory muster and will get filed soon; however, neither the investing public nor I think that is a lead pipe cinch to happen.
Well, rmsacc, I just don't think the company can last too much longer without some significant clinical successes. Patents mean something only if it works. It is the clinical verification that is needed. If the company languishes another year or more--or probably even another six or seven months--it will be in dire financial straits. It will be at best able to get through p2 for enhanced dermal scarring. There will not be money for any optical, non-scarring dermal or anything else. Pavco and the advisers will start leaving for more immediate, financially sound pastures and work will grind to a halt.
I just do not share your blissful assumptions that there is no rush to prove anything. We do need some more evidence of efficacy (we have very little now) soon in order to keep the doors open.
I might be wrong. I hope I am wrong. I don't think I am.
Not to be too cynical, rmsacc, but the fact that four insiders other than Geert bought into the secondary tells us very little. Two of the buys, by uber rich directors, were for 37,000 shares, or $14,000 and two (including Pavco, the head of clinical operations) were for 12,000 shares, or $4800. Those paltry amounts do not show me anything, other than possibly embarrassment at having not supported the company at all previously.
There is no reason to expect good things based on insiders other than Geert.
The money in the kitty is not so much. The price is too low currently to again go to the well for an infusion of equity capital. There has been no fundamental news in a very long time.
Unless we get some some positive motivating news soon, I think we are in trouble. I might be wrong. We might be able to go for several more months with no catalysts announced and still get a good deal or two or even a buyout. Unfortunately, things don't usually work that way. When the cupboard is almost bare, few white knights come riding in with anything but crumbs.
In my humble opinion, Rxi needs to show its fundamental strength very soon or it will die on the vine. I am NOT saying that positive motivating news will not appear soon; I am just saying that it dang well better appear soon.
I think they might, and it might not pertain just to market shenanigans. We should get a better idea in two weeks when Rxi holds a conference call. In the meantime, the doubters are in charge of the price.
"But had these forces themselves been neutral, up volume could have produced a 2-3 cent increase for the day."
Had the dog not stopped to relieve himself, he would have caught the rabbit.
"We are very close to filing our investigational new drug application with the FDA so that we can start clinical trials in retinal scarring."
Two months ago Geert said Rxi Pharma was "very close" to filing and IND for retinal scarring. I am not sure what the vague term "very close," means to Geert; however, I would think that two months is enough to qualify.
I find nothing to fault in biotechpicklist's message. There is every reason to think that sd-rxrnai will be able to accomplish the tasks that biotechpicklist seems assured of. I just wish we would get a little more confirmation soon.
"Did you see TKMR? They have a $300 mil market cap and they just failed their ebola trial. Now they combined their assets with another biotech to only focus on HBV assets. But what about the cancer programs Tekmira was working on with their LNP platform?
Rxi's delivery is easy, transfect all cells, and is delivered without any shields or particles. Rxi's tech IMO is revolutionary in the field of RNAi.
Alnylam -- requires Galnac shields to deliver RNAi systemically
Tekmira -- requires LNP -- lipid nanoparticles
ARWR -- requires a Dynamic polyconjugate shield which acts like a virus to reach targets
etc. All these other RNAi companies require the ability to create a barrier around the RNAi molecule to allow it to reach the target, The problem? it takes away from efficacy and creates toxicity.
Rxi's sd-rxRNA tech on the other hand is an RNAi molecule turned into a hybrid drug compound that requres no shields or delivery vehicles to reach its targets. People will soon understand why Rxi's tech is powerful."
Biotechpicklist tene is right, your post is good. In fact, it is more than good. It is brilliant.
You should email it to Geert. I'm not sure he understands all that, or is able communicate it to potential investors and/or deal partners/buyout partners.
I have them on ignore. They have no life and just like any vagrant, they have to hang around somewhere. Nobody cares about them or is influenced by them, but like fleas they are annoying.
I meant to address my post to autumn. But I guess it addresses the remarks of both tene and autumn.
tene, if everything finally "came together" for rxii things would be absolutely over the moon. It is almost unimaginable what the value of the current pipeline would be--let alone all the other potential applications for sd-rxrnai--in such a case.
I am not so sure, however, that things are "looking good for rxii." We have no results from the enhanced protocols for dermal scarring, and the early results (even if positive) will not tell us a whole lot. Secondly, the delay on the retinal scarring IND filing has me a bit concerned. Will it actually get done?
In sum: The potential is good. It is mind boggling. I don't know how good we look for eventually reaching that potential. I have my fingers crossed but my eyes wide open.
After closing on May 27 the secondary at .40 was announced. On May 28 the stock gapped down tremendously on historically high volume. We spent the next five weeks or so repairing the damage--we filled the gap and even had a nice rally to the low 60s. Then we slid again, seemed to be setting up for a rally back, and instead fell again a couple of days ago. We are now back to exactly where we we right before the announcement of the big dilution.
You might or might not be interested in a recitation of the recent trading pattern. I think it tells an important tale, and the tale is not so encouraging. If we fall into the gap opened by the secondary back at the end of May, it would not be good at all, imo.
Do your own thinking.
"Anymore the whole thing is under whatever conglomerate Tang is storing his excess shares in while he continues to destroy the share price."
I think you are right to be angry with and suspicious of Geert. I think you are just wrong to think Tang is in any way still involved with rxii. Tang made a bundle here and is now history, imo.